Biotech Values

[poorgradstudent]

ARRY:

I honestly don't understand its decision process. As if it doesn't have enough on its plate already with 520 and 614 which are supposed to be in pivotal trials soon, it has to run a ph3 trial based on data not from MEK162, rather from Selumetinib, without selection of RAS/RAF marker.

I guess this is, in part, what I was getting at. If this indication is worth investing in, then why wouldn't NVS take the lead as they've done for melanoma?

Or do NVS / ARRY have internal data that show the LGSOC indication to be low hanging fruit, and NVS is letting ARRY lead the charge so that they gain some development expertise?

I do think too many programs is a red flag for early stage biotechs, so I wonder what is really motivating ARRY here.